These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19808911)

  • 1. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Haffner SM; Viberti G; Herman WH; Lachin JM; Kravitz BG; Yu D; Paul G; Holman RR; Zinman B;
    Diabetes Care; 2010 Jan; 33(1):177-83. PubMed ID: 19808911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    Kahn SE; Haffner SM; Heise MA; Herman WH; Holman RR; Jones NP; Kravitz BG; Lachin JM; O'Neill MC; Zinman B; Viberti G;
    N Engl J Med; 2006 Dec; 355(23):2427-43. PubMed ID: 17145742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
    Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
    Dailey GE; Noor MA; Park JS; Bruce S; Fiedorek FT
    Am J Med; 2004 Feb; 116(4):223-9. PubMed ID: 14969649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
    Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
    Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
    Kahn SE; Lachin JM; Zinman B; Haffner SM; Aftring RP; Paul G; Kravitz BG; Herman WH; Viberti G; Holman RR;
    Diabetes; 2011 May; 60(5):1552-60. PubMed ID: 21415383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
    Kelly AS; Thelen AM; Kaiser DR; Gonzalez-Campoy JM; Bank AJ
    Vasc Med; 2007 Nov; 12(4):311-8. PubMed ID: 18048467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G;
    Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
    Reyes-Morales H; Mino-León D; Doubova SV; Flores-Hernández S
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):1-9. PubMed ID: 22192639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus.
    Pop-Busui R; Oral E; Raffel D; Byun J; Bajirovic V; Vivekanandan-Giri A; Kellogg A; Pennathur S; Stevens MJ
    Metabolism; 2009 Jul; 58(7):989-94. PubMed ID: 19394661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
    Goldstein BJ; Weissman PN; Wooddell MJ; Waterhouse BR; Cobitz AR
    Curr Med Res Opin; 2006 Sep; 22(9):1715-23. PubMed ID: 16968575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy.
    Putz DM; Goldner WS; Bar RS; Haynes WG; Sivitz WI
    Metabolism; 2004 Nov; 53(11):1454-61. PubMed ID: 15536601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.
    Gupta M; Braga MB; Verma S
    Can J Cardiol; 2008 Oct; 24(10):e65-9. PubMed ID: 18841263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
    Scheen AJ
    Rev Med Liege; 2007 Jan; 62(1):48-52. PubMed ID: 17343130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007.
    Cross JT; Veenstra DL; Gardner JS; Garrison LP
    Clin Pharmacol Ther; 2011 Mar; 89(3):429-36. PubMed ID: 21289618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
    Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
    Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
    Home PD; Kahn SE; Jones NP; Noronha D; Beck-Nielsen H; Viberti G; ;
    Diabetologia; 2010 Sep; 53(9):1838-45. PubMed ID: 20532476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ADOPT study. Glitazone controls diabetes progression].
    Einecke D
    MMW Fortschr Med; 2007 Jan; 149(1-2):10, 12, 14. PubMed ID: 17619358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.